Measurement of adenylate cyclase activity in the right ventricular endomyocardial biopsy samples from patients with chronic congestive heart failure
- PMID: 10683613
- PMCID: PMC6808086
- DOI: 10.1002/(sici)1098-2825(2000)14:2<48::aid-jcla2>3.0.co;2-z
Measurement of adenylate cyclase activity in the right ventricular endomyocardial biopsy samples from patients with chronic congestive heart failure
Abstract
A highly sensitive fluorometric assay technique was adopted in order to examine the adenylate cyclase activity in the minute right ventricular endomyocardial biopsy samples from patients with chronic congestive heart failure (n = 10). Norepinephrine (10(-4) M) and adenosine (10(-3) M) were incubated for 30 min with 10 microl of membrane preparation (1-2 mg protein/mg) to analyze the extent of the receptor-coupled adenylate cyclase activity. Forskolin (10(-4) M) stimulation was used to estimate the maximum adenylate cyclase activity (pmol/mg protein/min, mean +/- SE). The new microanalytical cyclic AMP assay involves four steps: enzymatic destruction of noncyclic adenine nucleotides and phosphorylated metabolites, conversion of cyclic AMP to ATP, amplification of ATP by enzymatic cycling, and fluorometric measurement of NADPH, which is generated in proportion to initial cyclic AMP levels. Basal and forskolin-stimulated maximum adenylate cyclase activities were 75 +/- 8 and 123 +/- 15, respectively. Norepinephrine increased the adenylate cyclase activity to 107 +/- 14, while adenosine tended to decrease it to 65 +/- 7. In addition, elimination of adenosine by adenosine deaminase (10 U/ml) slightly increased the adenylate cyclase activity to 82 +/- 9. These results indicate that the adenylate cyclase activity can be measured in minute endomyocardial biopsy samples. Use of this new approach shows promise of becoming a new and potentially important way to predict the efficacy of pharmacological treatment.
Copyright 2000 Wiley-Liss, Inc.
References
-
- Hershberger RE, Feldman AM, Bristow MR. A1‐adenosine receptor inhibition of adenylate cyclase in failing and nonfailing human ventricular myocardium. Circulation 1991;83:1343–1351. - PubMed
-
- Bristow MR, Hershberger RE, Port JD, Minobe W, Rasmussen R. β1‐ and β2‐adrenergic receptor‐mediated adenylate cyclase stimulation in nonfailing and failing human ventricular myocardium. Mol Pharmacol 1989;35:295–303. - PubMed
-
- Cruz Caturla M, Masotti M, Brodde OE, et al. Development of myocardial beta‐adrenergic receptor density and adenylate cyclase activity after human heart transplantation. J Heart Lung Transplant 1992;11:1059–1065. - PubMed
-
- Reithmann C, von Scheidt W, Werdan K. Beta‐adrenoceptor desensitization despite cardiac denervation in human failing transplanted myocardium. Int J Cardiol 1996;56:11–15. - PubMed
-
- Loh E, Barnett JV, Feldman AM, et al. Decreased adenylate cyclase activity and expression of Gsα in human myocardium after orthotopic cardiac transplantation. Circ Res 1995;76:852–860. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials